Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Featured trial
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 84 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 184 views
  • 25 Mar, 2021
  • 1 location
Defining Predictors of RT Response to Vedolizumab in IBD

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify

  • 12 views
  • 04 Mar, 2022
  • 1 location
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated

vedolizumab
adalimumab
azathioprine
corticosteroids
tumor necrosis factor
  • 0 views
  • 24 Mar, 2022
  • 1 location
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.

vedolizumab
fecal microbiota transplantation
enemas
microbiota
tumor necrosis factor
  • 0 views
  • 16 Sep, 2021
  • 1 location
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative

  • 8 views
  • 24 May, 2022
  • 19 locations
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of …

  • 0 views
  • 11 Apr, 2021
  • 1 location
Vedolizumab for Immune Mediated Colitis

This is an open label randomized trial to evaluate the efficacy and treatment duration with vedolizumab to patients with immune mediated colitis. The trial will include 82 patients randomized

  • 0 views
  • 17 Oct, 2021
  • 1 location
Fecal Microbial Transplantation and Vedolizumab Treatment of Crohn's Disease

The investigators postulate that by determining a patient's baseline microbiome and manipulating it through fecal microbial transplantation (FMT) may improve response rates to vedolizumab in

remission
vedolizumab
crohn's disease
  • 10 views
  • 03 Mar, 2022
  • 2 locations
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease (VEDO-PREDIRESP)

Vedolizumab (VDZ) is a monoclonal antibody which has shown its efficacy in Crohn's disease by inducing and maintaining clinical response/remission. The French marketing authorization was

vedolizumab
antibiotics
mesalamine
azathioprine
monoclonal antibodies
  • 0 views
  • 26 Jan, 2022
  • 4 locations